Crohn's Disease
Frequent antibiotic use, diet rich in sweets, urban living heighten risk for pediatric IBD
CHICAGO — A diet rich in sweetened candy or drinks, exposure to antibiotics during early childhood and urban living were among risk factors for developing pediatric inflammatory bowel disease, according to data at Digestive Disease Week.
VIDEO: No change in concomitant medications after Rebyota for recurrent C. difficile, IBD
CHICAGO — Treatment with Rebyota did not affect concurrent medication use in patients with inflammatory bowel disease and recurrent Clostridioides difficile infection, Jessica R. Allegretti, MD, MPH, explains in this Healio video.
Colonoscopy withdrawal time of 15 minutes boosts polypoid dysplasia detection in IBD
CHICAGO — Colonoscopy withdrawal time was independently associated with polypoid dysplasia detection in patients with inflammatory bowel disease, with a cutoff time of at least 15 minutes linked to increased odds for detection.
Vedolizumab, ustekinumab induce similar rates of clinical response, remission in Crohn’s
CHICAGO — Biologic-naive patients treated with vedolizumab and ustekinumab for Crohn’s disease had similar rates of clinical response and remission, although mucosal healing and biologic treatment persistence differed at 36 months.
Immunoprophylaxis ‘does not seem superior’ to prevent postoperative Crohn’s recurrence
CHICAGO — Immediate immunoprophylaxis after curative ileo-colonic resection did not reduce the rate of early recurrence among patients with Crohn’s disease who only had one risk factor for postoperative recurrence.
Ileocecal resection may have role as ‘primary treatment’ in recently diagnosed Crohn’s
CHICAGO — Patients who underwent ileocecal resection for Crohn’s disease had a 33% lower risk for hospitalization, repeat surgery, systemic corticosteroid exposure and perianal CD, according to a presenter at Digestive Disease Week.
First patients enrolled in US trial of nerve stimulation device for IBD
Boomerang Medical announced that the first patients have been enrolled in its U.S. clinical trial assessing the use of nerve stimulation as potential treatment for Crohn’s disease and ulcerative colitis.
Adalimumab plus methotrexate lowers treatment failure 2-fold in pediatric Crohn’s
Combination therapy with adalimumab plus low-dose methotrexate induced a two-fold reduction of treatment failure among pediatric patients with Crohn’s disease, according to research published in Gastroenterology.
Subcutaneous infliximab could ‘transform’ how patients with IBD navigate care
Subcutaneous infliximab achieved greater clinical remission and endoscopic response rates compared with placebo in patients with inflammatory bowel disease and has potential to become a more convenient, “patient-centric” treatment option.
IBD care updates of 2023 (so far): Promising strategies to improve patient quality of life
Two of the most important goals in the treatment of patients with inflammatory bowel disease are to improve patient quality of life and increases the odds of remission.